Article Text

Download PDFPDF

OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
Free
  1. Christopher T. Ritchlin1,
  2. Arthur Kavanaugh2,
  3. Joseph F. Merola3,
  4. Georg Schett4,
  5. Jose U. Scher5,
  6. Richard B. Warren6,
  7. Deepak Assudani7,
  8. Thomas Kumke8,
  9. Barbara Ink7,
  10. Iain Mcinnes9
  1. 1University of Rochester Medical Centre, Rochester, United States of America
  2. 2UC San Diego School of Medicine, La Jolla, United States of America
  3. 3Harvard Medical School, Brigham and Women’s Hospital, Boston, United States of America
  4. 4Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany
  5. 5NYU Langone Medical Center, Department of Medicine, New York, United States of America
  6. 6The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom
  7. 7UCB Pharma, Slough, United Kingdom
  8. 8UCB Pharma, Monheim am Rhein, Germany
  9. 9University of Glasgow, Glasgow, United Kingdom

Abstract

Background IL-17F shares structural homology and pro-inflammatory function with IL–17A. Preclinical and early clinical data support neutralisation of IL-17F, in addition to IL–17A, as a novel targeting approach in psoriatic disease.

Objectives The objective of this Phase 2b study (NCT02969525) was to assess the dose response, long-term efficacy and safety of bimekizumab (BKZ), a mAb that potently and selectively neutralises IL-17A and IL-17F, over 48 weeks in patients (pts) with active PsA.

Methods 206 pts with active PsA, ≥3/76 swollen joint count, ≥3/78 tender joint count and CASPAR score ≥3, were randomised (1:1:1:1:1) to receive subcutaneous BKZ 16mg, 160mg, 160mg with 320mg loading dose (160mg [LD]), 320mg or placebo (PBO) Q4W, for 12 weeks (double-blind period). After Week 12, pts receiving PBO or BKZ 16mg were re-randomised (1:1) to BKZ 160mg or 320mg; all other pts continued on their initial dose (dose-blind period). The primary endpoint was ACR50 response at Week 12.

Results 203/206 and 189/206 pts completed the double- and dose-blind periods, respectively. Overall, demographics and baseline disease characteristics were balanced across groups. 19% of pts had prior exposure to TNF inhibitors (TNFi). There was a statistically significant (p<0.05) dose-response at Week 12 for ACR50 response rates. At Week 12, significantly more pts receiving BKZ versus PBO achieved ACR50 (primary endpoint: 16–160mg [LD] doses), ACR20 and PASI90 (in those pts with baseline body surface area ≥3%; 160–320mg doses) (table). ACR20/50/70, PASI75/90/100, MDA and resolution of enthesitis response rates increased between Week 12 and Week 24 in those continuing on their initial BKZ dose; Week 24 responses were maintained through the study; responses were similar across the three highest dose groups at Week 48 (PASI100 analyses were post hoc). Rapid improvements were observed across all response criteria in pts re–allocated to BKZ 160 or 320mg (table). BKZ-treated pts naïve to TNFi achieved ACR20/50 and PASI90/100 at comparable rates to the overall population at Week 12 and 48. There was no apparent relationship between dose and TEAEs. Serious AEs were reported by 9/206 (4.4%) pts up to Week 48 (8/206 [3.9%] patients were receiving BKZ). The most common TEAE up to Week 48 was nasopharyngitis 25/206 [12.1%]). Oral candidiasis was reported at Week 48 by 10/206 (4.9%) pts (all cases during BKZ treatment). No deaths, or cases of IBD or MACE were reported.

Conclusion Dual neutralisation of IL-17A and IL-17F with BKZ provided substantial improvements in both musculoskeletal and skin outcomes; response rates increased after Week 12 (primary analysis) and were sustained from Week 24 to 48, with a safety profile consistent with previous BKZ studies. These data provide further support that neutralising IL–17F in addition to IL-17A with BKZ is a promising therapeutic approach in pts with active PsA.

Acknowledgement Funded by UCB Pharma.

Disclosure of Interests Christopher T. Ritchlin Grant/research support from: AbbVie, Amgen, UCB Pharma, Consultant for: AbbVie, Amgen, Lilly, Novartis, Pfizer, UCB Pharma, Arthur Kavanaugh Grant/research support from: UCB Pharma, Joseph F. Merola Consultant for: Biogen IDEC, Abbvie, Amgen, Eli Lilly and Company, Novartis, Pfizer, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, Merck, and GSK, Georg Schett: None declared, Jose U. Scher Consultant for: BMS, Janssen, Novartis, UCB Pharma, Richard B. Warren Grant/research support from: AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO, Novartis, Pfizer, UCB Pharma, Consultant for: AbbVie, Almirall, Amgen, Boehringer-Ingleheim, Celgene, Janssen, LEO, Lilly, Novartis, Pfizer, Sanofi, UCB, Xenoport, Deepak Assudani Shareholder of: UCB Pharma, Employee of: UCB Pharma, Thomas Kumke Employee of: UCB Pharma, Barbara Ink Shareholder of: GSK, UCB Pharma, Employee of: UCB Pharma, Iain McInnes Grant/research support from: AstraZeneca, Celgene, Compugen, Novartis, Roche, UCB Pharma, Consultant for: AbbVie, Celgene, Galvani, Lilly, Novartis, Pfizer, UCB Pharma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.